BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Chatterjee S, Ghosal S, Chatterjee S. Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome. World J Diabetes 2016; 7(18): 441-448 [PMID: 27795818 DOI: 10.4239/wjd.v7.i18.441]
URL: https://www.wjgnet.com/1948-9358/full/v7/i18/441.htm
Number Citing Articles
1
Miles Congreve, John A. Christopher, Chris Graaf. Burger's Medicinal Chemistry and Drug Discovery2021; : 1 doi: 10.1002/0471266949.bmc269
2
Mark F McCarty, Aaron Lerner. Perspective: Prospects for Nutraceutical Support of Intestinal Barrier FunctionAdvances in Nutrition 2021; 12(2): 316 doi: 10.1093/advances/nmaa139
3
Yajie Dong, Qingguo Lv, Sheyu Li, Yuan Wu, Ling Li, Juan Li, Fang Zhang, Xin Sun, Nanwei Tong. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysisClinics and Research in Hepatology and Gastroenterology 2017; 41(3): 284 doi: 10.1016/j.clinre.2016.11.009
4
Carol H. Wysham, Carlos Campos, Davida Kruger. Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic MedicationsClinical Diabetes 2018; 36(2): 149 doi: 10.2337/cd17-0064
5
Hidetaka Hamasaki. Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment?World Journal of Diabetes 2018; 9(8): 138-140 doi: 10.4239/wjd.v9.i8.138
6
Vimala Ananthy, Raman Palanyswamy Priyadharsini, Umamaheswari Subramanian. Pathogenesis, Diagnosis, and Management of Metabolic Syndrome: A Comprehensive ReviewSBV Journal of Basic, Clinical and Applied Health Science 2021; 4(2): 39 doi: 10.5005/jp-journals-10082-03111
7
Rajesh Rajput, Sujoy Ghosh, Samar Banerjee, Beena Bansal, Manoj Chawla, AbhayI Ahluwalia, Tejal Lathia, AshokK Das. First-in-class oral semaglutide: Overcoming barriers of incretinisation in the Indian contextIndian Journal of Endocrinology and Metabolism 2022; 26(5): 417 doi: 10.4103/ijem.ijem_217_22
8
Andrea Bortolato, Jonathan S. Mason. Contemporary Accounts in Drug Discovery and Development2022; : 179 doi: 10.1002/9781119627784.ch9
9
Ting Xiang, Siliang Zhang, Qinge Li, Ling Li, Hua Liu, Chen Chen, Gangyi Yang, Mengliu Yang. GPHB5 Is a Biomarker in Women With Metabolic Syndrome: Results From Cross-Sectional and Intervention StudiesFrontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.893142
10
Raphael Alhadeff, Arieh Warshel. A free‐energy landscape for the glucagon‐like peptide 1 receptor GLP1RProteins: Structure, Function, and Bioinformatics 2020; 88(1): 127 doi: 10.1002/prot.25777
11
Ming Wang, Gwangho Yoon, Juhyun Song, Jihoon Jo. Exendin-4 improves long-term potentiation and neuronal dendritic growth in vivo and in vitro obesity conditionScientific Reports 2021; 11(1) doi: 10.1038/s41598-021-87809-4
12
Haaglim Cho, JungIn Um, Ji-Hyung Lee, Woong-Hee Kim, Wan Seok Kang, So Hun Kim, Hyung-Ho Ha, Yong-Chul Kim, Young-Keun Ahn, Da-Woon Jung, Darren R. Williams. ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetesScientific Reports 2017; 7(1) doi: 10.1038/srep44186
13
Olusola F. Onoviran, Dongming Li, Sarah Toombs Smith, Mukaila A. Raji. Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitusTherapeutic Advances in Chronic Disease 2019; 10: 204062231986269 doi: 10.1177/2040622319862691
14
Sanjay Kalra, Ashok Kumar Das, Rakesh Kumar Sahay, Manash Pratim Baruah, Mangesh Tiwaskar, Sambit Das, Sudip Chatterjee, Banshi Saboo, Ganapathi Bantwal, Saptarshi Bhattacharya, Gagan Priya, Manoj Chawla, Kiraninder Brar, Syed Abbas Raza, Azizul Hasan Aamir, Dina Shrestha, Noel Somasundaram, Prasad Katulanda, Faria Afsana, Shahjada Selim, Mohammad Wali Naseri, Ali Latheef, Manilka Sumanatilleke. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task ForceDiabetes Therapy 2019; 10(5): 1645 doi: 10.1007/s13300-019-0669-4
15
Holly J. Kramer, Shivam Joshi. Nutritional Management of Renal Disease2022; : 763 doi: 10.1016/B978-0-12-818540-7.00028-8
16
Ali Jazayeri, Mathieu Rappas, Alastair J. H. Brown, James Kean, James C. Errey, Nathan J. Robertson, Cédric Fiez-Vandal, Stephen P. Andrews, Miles Congreve, Andrea Bortolato, Jonathan S. Mason, Asma H. Baig, Iryna Teobald, Andrew S. Doré, Malcolm Weir, Robert M. Cooke, Fiona H. Marshall. Crystal structure of the GLP-1 receptor bound to a peptide agonistNature 2017; 546(7657): 254 doi: 10.1038/nature22800
17
Elizabeth G. Mietlicki-Baase, Lauren E. McGrath, Kieran Koch-Laskowski, Joanna Krawczyk, Tram Pham, Rinzin Lhamo, David J. Reiner, Matthew R. Hayes. Hindbrain DPP-IV inhibition improves glycemic control and promotes negative energy balancePhysiology & Behavior 2017; 173: 9 doi: 10.1016/j.physbeh.2017.01.038
18
Nabilah Ibnat, Rahela Zaman, Mohammad Borhan Uddin, Ezharul Chowdhury, Chooi Yeng Lee. Improved systemic half-life of glucagon-like peptide-1-loaded carbonate apatite nanoparticles in ratsWorld Journal of Diabetes 2022; 13(8): 613-621 doi: 10.4239/wjd.v13.i8.613
19
Lei Zhang, Shi-Tao Zhang, Yan-Chun Yin, Shu Xing, Wan-Nan Li, Xue-Qi Fu. Hypoglycemic effect and mechanism of isoquercitrin as an inhibitor of dipeptidyl peptidase-4 in type 2 diabetic miceRSC Advances 2018; 8(27): 14967 doi: 10.1039/C8RA00675J